Accessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

VVOS Stock Rises: Clinical Trial Success Sparks Interest

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 7/1/2025, 9:18 am ET 6 min read
VVOS Stock Rises: Clinical Trial Success Sparks Interest Thumbnail

In this article

  • VVOS+27.53%
    VVOS - NASDAQVivos Therapeutics Inc.
    $4.03+0.87 (+27.53%)
    Volume:  17.15M
    Float:  5.74M
    $3.17Day Low/High$6.65

Vivos Therapeutics Inc.’s stocks have been trading up by 39.24 percent after promising FDA designations spurred investor confidence.

Clinical Trial Results Boost VVOS

  • Vivos Therapeutics has unveiled promising clinical trial results in a study published by the European Journal of Pediatrics concerning its Daytime-Nighttime Appliance (DNA) for kids with obstructive sleep apnea (OSA). Out of the patients evaluated, 79% showed improvement in their OSA symptoms.

  • Notably, 17% of the children achieved complete resolution of their OSA symptoms, while 93% experienced a reduction in symptoms by half, showcasing the DNA device’s effectiveness without any safety concerns reported.

  • Recently, Vivos received FDA 510(k) clearance in September 2024 for the DNA device to treat moderate to severe pediatric OSA, enhancing the company’s reputation and opening potential market opportunities.

Candlestick Chart

Live Update At 09:18:26 EST: On Tuesday, July 01, 2025 Vivos Therapeutics Inc. stock [NASDAQ: VVOS] is trending up by 39.24%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Vivos Therapeutics Inc.’s Earnings Overview

When it comes to mastering the world of trading, it’s important to remember that success isn’t about striking it rich overnight. As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” This mindset forms the backbone of a resilient trading strategy. By consistently aiming for modest gains rather than high-risk, quick-profit opportunities, traders can cultivate a portfolio that thrives over time. Hence, patience and persistent efforts play a crucial role in ensuring long-term success in trading.

Delving into Vivos Therapeutics’ recent performance, it’s crucial to recognize the earnings and financial strategies that continue to shape the company’s trajectory. The latest financial reports painted a robust yet challenging picture for Vivos. The company’s revenue reached $15.03M, showcasing a growth trajectory that once seemed distant. However, the broader financial landscape remains complex.

Operating expenses remain high, partially attributed to ongoing R&D and expansion strategies. With total expenses reaching $6.93M, pressure is building on the company to continuously improve its profit margins. The gross profit stands at $1.5M, indicating the ongoing battle to balance investments in growth against rising operational costs. Despite these challenges, Vivos’ financial health, with tangible assets around $11.28M, continues to provide a buffer for unforeseen economic shifts.

More Breaking News

Key ratios reveal deeper insights: with a price-to-sales ratio of 1.32 and a price-to-book ratio hovering at 4.38, the market might perceive Vivos under agonizing pressure to optimize its sales and revenue streams. However, the company’s commitment to innovation, especially through its clinically successful DNA device, suggests potential for an optimistic turnaround.

Market Implications and Stock Movements

The release of positive clinical trial results sparked investor interest, reflected in stock volatility. Examining the recent trading activity shows a mix of ebbs and flows amid these disclosures. On Jun 30, 2025, the VVOS stock closed at $3.16, showcasing minor fluctuations throughout the period. Yet, the anticipation built around FDA clearance and the trial results indicates potential upward momentum for the stock.

The intraday chart offers a glimpse of trader sentiments. Starting the day at $4.4 and quickly oscillating in response to news, the stock’s movements highlight the financial community’s collective reactions and calculated risk-taking. Advances in the clinical space often propel stocks like VVOS into the trading limelight, especially when results offer tangible benefits alongside regulatory endorsements.

Financial Predictions and Growth Trajectories

Financially, Vivos Therapeutics treads a delicate line between growth and financial restructuring. With significant expenditure directed towards advancing medical devices and technology, sustainably converting these into higher margins remains pivotal. Management effectiveness ratios, depicting returns on assets and equity, further underscore the need for strategic recalibration for sustained investor confidence.

Moving forward, key focus areas include extending market reach for their DNA device, optimizing manufacturing and distribution, and continually reinforcing their market position.

Concluding Thoughts on VVOS

The successful trial results for the DNA device, coupled with recent FDA approval, reshape the future for Vivos Therapeutics. As the company strategically navigates financial complexities, keeping a close watch on stock movements and clinical advancements becomes essential. The company stands on a precipice of potential growth and opportunity, contingent on executing its growth strategies and stabilizing financial health. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” Therefore, effective fiscal management and trading strategies will be pivotal in ensuring sustained success.

Vivos Therapeutics’ journey, much like that of many breakthrough companies, is the narrative of hope balanced with reality. As they continue to pioneer in pediatric OSA treatment, their path is undoubtedly one to watch. Nonetheless, market dynamics and financial indicators will remain crucial determinants of the road ahead.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

In this article (YTD Performance)

  • VVOS-4.13%
    VVOS - NASDAQVivos Therapeutics Inc.
    $4.03+0.87 (+27.53%)
    Volume:  17.15M
    Float:  5.74M
    $3.17Day Low/High$6.65

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM
notification icon
Subscribe to receive notifications